Fig. 4.
Effect of Nrf2 activator compounds on NQO1 mRNA expression and NQO1 activity in alveolar macrophages from S and COPD patients. Alveolar macrophages from COPD patients (n = 8) (A and C) and S (n = 8) (B and D) were treated with CDDO (0.3–100 nM), GSK7 (1–1000 nM), C4X_6665 (0.3–30 nM), Sulforaphane (1000–10,000 nM), MMF (1000–10,000 nM) or vehicle control (DMSO) for 24 h for qPCR (A, B) or 48 h for activity assay (C, D). NQO1 mRNA expression was assessed by RT-qPCR (A, B) and NQO1 activity was assessed by NQO1 activity enzyme assay (C, D). Data presented as mean ± SEM fold increase above DMSO control (RT-qPCR data 2−ΔΔCt). *, **, *** = significantly above DMSO control (p < 0.05, p < 0.01 and p < 0.001, respectively)